Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients

BACKGROUND: Neurofibromatosis type 2 (NF2)-related schwannomatosis is an autosomal dominant tumor-predisposition syndrome characterized by bilateral vestibular schwannomas (VS). In patients with VS associated with NF2, vascular endothelial growth factor A inhibitor, bevacizumab, is a systemic treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, M J, Neth, Bryan J, Webb, Lauren M, Van Gompel, Jamie J, Link, Michael J, Neff, Brian A, Carlson, Matthew L, Driscoll, Colin L, Dornhoffer, Jim, Ruff, Michael W, Anderson, Kelsey A, Kizilbash, Sani H, Campian, Jian L, Uhm, Joon H, Lane, Jack I, Benson, John C, Blezek, Daniel J, Mehta, Parv M, Bathla, Girish, Sener, Ugur T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576512/
https://www.ncbi.nlm.nih.gov/pubmed/37841698
http://dx.doi.org/10.1093/noajnl/vdad123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576512/
https://www.ncbi.nlm.nih.gov/pubmed/37841698
http://dx.doi.org/10.1093/noajnl/vdad123

Ejemplares similares